Protalix BioTherapeutics Inc (PLX)
1.11
-0.14
(-11.20%)
USD |
NYAM |
May 10, 16:00
1.11
0.00 (0.00%)
After-Hours: 16:45
Protalix BioTherapeutics Enterprise Value: 67.01M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 09, 2024 | 67.01M |
May 08, 2024 | 58.97M |
May 07, 2024 | 58.97M |
May 06, 2024 | 56.78M |
May 03, 2024 | 58.97M |
May 02, 2024 | 60.43M |
May 01, 2024 | 64.08M |
April 30, 2024 | 58.97M |
April 29, 2024 | 63.35M |
April 26, 2024 | 59.70M |
April 25, 2024 | 61.89M |
April 24, 2024 | 64.08M |
April 23, 2024 | 63.35M |
April 22, 2024 | 61.89M |
April 19, 2024 | 59.70M |
April 18, 2024 | 58.24M |
April 17, 2024 | 59.70M |
April 16, 2024 | 58.97M |
April 15, 2024 | 58.97M |
April 12, 2024 | 61.89M |
April 11, 2024 | 64.81M |
April 10, 2024 | 67.74M |
April 09, 2024 | 72.12M |
April 08, 2024 | 70.66M |
April 05, 2024 | 61.16M |
Date | Value |
---|---|
April 04, 2024 | 64.08M |
April 03, 2024 | 66.28M |
April 02, 2024 | 66.28M |
April 01, 2024 | 67.01M |
March 28, 2024 | 67.74M |
March 27, 2024 | 67.01M |
March 26, 2024 | 64.81M |
March 25, 2024 | 64.81M |
March 22, 2024 | 68.47M |
March 21, 2024 | 72.12M |
March 20, 2024 | 73.58M |
March 19, 2024 | 70.66M |
March 18, 2024 | 68.47M |
March 15, 2024 | 72.85M |
March 14, 2024 | 75.77M |
March 13, 2024 | 86.73M |
March 12, 2024 | 80.16M |
March 11, 2024 | 80.89M |
March 08, 2024 | 84.54M |
March 07, 2024 | 82.35M |
March 06, 2024 | 83.81M |
March 05, 2024 | 86.73M |
March 04, 2024 | 90.38M |
March 01, 2024 | 94.04M |
February 29, 2024 | 94.60M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
19.45M
Minimum
Dec 03 2021
274.11M
Maximum
Feb 24 2021
92.91M
Average
84.10M
Median
Jul 16 2019
Enterprise Value Benchmarks
Agenus Inc | 194.03M |
InfuSystems Holdings Inc | 189.63M |
AIM ImmunoTech Inc | 9.406M |
Perspective Therapeutics Inc | 1.049B |
Armata Pharmaceuticals Inc | 186.62M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -6.044M |
Revenue (Quarterly) | 10.49M |
Total Expenses (Quarterly) | 16.10M |
EPS Diluted (Quarterly) | -0.10 |
Gross Profit Margin (Quarterly) | 15.54% |
Profit Margin (Quarterly) | -57.64% |
Earnings Yield | 1.80% |
Operating Earnings Yield | 12.12% |
Normalized Earnings Yield | 1.802 |